European ScreeningPort GmbH set up in Hamburg, supported by Evotec and govt
Hamburg is set to become a leading hub of Europe's academic drug discovery, with the northern German city announcing the foundation of European ScreeningPort GmbH, a company that will run a state-of-the-art drug discovery service center. The firm is being established with the support of the German Federal Ministry of Education and Research, the Free and Hanseatic City of Hamburg, Evotec AG and Norgenta, the north German life science agency. Although still in an early phase, the project has already raised more than 7.0 million euros ($9.5 million) in financing.
European ScreeningPort will build on research results generated in academia. It will enable a more systematic and efficient search for promising new compounds which can subsequently be further developed. Both Evotec and the City of Hamburg have invested into the newly-founded company, which will be run as a public/private partnership. This novel concept in advancing drug discovery will also be supported with considerable funds from the Ministry of Education and Research.
Provides link between pharma and academia
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze